Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Vidarabine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 known ✓ | P30542 | 3/20 | 0.80 |
| ▸ | ADORA3 known ✓ | P0DMS8 | 1/20 | 0.80 |
| ▸ | ADORA2A known ✓ | P29274 | 1/20 | 0.80 |
| ▸ | ADORA2B known ✓ | P29275 | 1/20 | 0.80 |
| ▸ | P2RY2 | P41231 | 4/20 | 0.82 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.80 |
| ▸ | DPP4 | P27487 | 1/20 | 0.80 |
| ▸ | MEN1 | O00255 | 1/20 | 0.80 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.80 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.80 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.80 |
| ▸ | GAPDH | P04406 | 1/20 | 0.80 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.80 |
| ▸ | STAT6 | P42226 | 1/20 | 0.80 |
| ▸ | PI4KA | P42356 | 1/20 | 0.80 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.80 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.80 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.80 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.80 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Adenosine SCHEMBL29796534 | 1.00 | P2RY2 (0.82) | P2RY2ADORA1SMN1; SMN2DPP4MEN1 | |
| Adenosine SCHEMBL1744580 | 1.00 | P2RY2 (0.82) | P2RY2ADORA1SMN1; SMN2DPP4MEN1 | |
| Adenosine SCHEMBL29397260 | 1.00 | P2RY2 (0.82) | P2RY2ADORA1SMN1; SMN2DPP4MEN1 | |
| Adenosine SCHEMBL2210868 | 1.00 | P2RY2 (0.82) | P2RY2ADORA1SMN1; SMN2DPP4MEN1 | |
| Adenosine SCHEMBL459770 | 0.99 | P2RY2 (0.80) | P2RY2ADORA1SMN1; SMN2DPP4MEN1 | |
| Adenosine SCHEMBL29362201 | 0.99 | P2RY2 (0.80) | P2RY2ADORA1SMN1; SMN2DPP4MEN1 | |
| Adenosine SCHEMBL28296801 | 0.99 | P2RY2 (0.80) | P2RY2ADORA1SMN1; SMN2DPP4MEN1 | |
| Adenosine SCHEMBL459996 | 0.99 | P2RY2 (0.80) | P2RY2ADORA1SMN1; SMN2DPP4MEN1 | |
| Adenosine SCHEMBL28186074 | 0.99 | P2RY2 (0.80) | P2RY2ADORA1SMN1; SMN2DPP4MEN1 | |
| Adenosine SCHEMBL28240733 | 0.99 | P2RY2 (0.80) | P2RY2ADORA1SMN1; SMN2DPP4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0415731-B1 | Novel entities for cancer therapy | WELLCOME FOUND (GB) | 2003-04-02 | — | — | EP | disclosed |
| CN-1058993-C | Preparation method and application of molecular chimera for treating cancer | WELLCOME FOUND (GB) | 2000-11-29 | — | — | CN | disclosed |
| CN-1162643-A | Preparation and usage of molecular chimera for curing cancer | WELLCOME FOUND (GB) | 1997-10-22 | — | — | CN | disclosed |
| EP-0690129-A1 | Novel entities for cancer therapy | THE WELLCOME FOUNDATION LIMITED (GB) | 1996-01-03 | — | — | EP | disclosed |
| EP-0657539-A1 | Novel entities for cancer therapy | THE WELLCOME FOUNDATION LIMITED (GB) | 1995-06-14 | — | — | EP | disclosed |
| EP-0657540-A1 | Novel entities for cancer therapy | THE WELLCOME FOUNDATION LIMITED (GB) | 1995-06-14 | — | — | EP | disclosed |
| EP-0657541-A1 | Novel entities for cancer therapy | THE WELLCOME FOUNDATION LIMITED (GB) | 1995-06-14 | — | — | EP | disclosed |
| CN-1050899-A | NOVEL ENTITIES FOR CANCER THERAPY | WELLCOME FOR CANCER THERAPY (GB) | 1991-04-24 | — | — | CN | disclosed |
| EP-0415731-A2 | Novel entities for cancer therapy | THE WELLCOME FOUNDATION LIMITED (GB) | 1991-03-06 | — | — | EP | disclosed |